SEC Contract Filing

Filing Date: 2018-03-23

Document Content:
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>4
<FILENAME>htgm-ex1031_817.htm
<DESCRIPTION>EX-10.31
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
htgm-ex1031_817.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 10.31</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***Text Omitted and Filed Separately</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with the Securities and Exchange Commission.</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential Treatment Requested</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under 17 C.F.R. Sections 200.80(b)(4)</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and 240.24b-2.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUPPLEMENT AGREEMENT</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">THIS SUPPLEMENT AGREEMENT (this &#8220;Supplement Agreement&#8221;) is effective&nbsp;&nbsp;June 2, 2017 (the &#8220;Effective Date&#8221;) and is made and entered into by and between&nbsp;&nbsp;HTG Molecular Diagnostics, Inc., having a place of business at 3430 E. Global Loop, Tucson, AZ 85706, U.S.A. (&#8220;<font style="text-decoration:underline;">HTG</font>&#8221;), QIAGEN Manchester Limited, having a place of business at Skelton House, Lloyd Street North, Manchester, M15 6SH, England (&#8220;<font style="text-decoration:underline;">QIAGEN</font>&#8221;), and Bristol-Myers Squibb Company, having a place of business at Route&#160;206 &amp; Province Line Road, Princeton, NJ 08543-4000, U.S.A. (&#8220;<font style="text-decoration:underline;">BMS</font>&#8221;). QIAGEN, HTG and BMS are collectively referred to as the &#8220;<font style="text-decoration:underline;">Parties</font>,&#8221; and each individually as a &#8220;<font style="text-decoration:underline;">Party</font>.&#8221;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">WHEREAS, HTG and QIAGEN entered into a Master Assay Development, Commercialization and Manufacturing Agreement dated as of November 16, 2016 (the &#8220;<font style="text-decoration:underline;">Master HTG/QIAGEN Agreement</font>&#8221;);</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">WHEREAS, QIAGEN and BMS entered into an Initiation Agreement having an effective date of June 2, 2017 and amended on July 17, 2017 and August 7, 2017 (collectively, and including any amendments subsequent to the date this Supplement Agreement is last signed by a Party hereto to which HTG consents, the &#8220;<font style="text-decoration:underline;">Initiation Agreement</font>&#8221;) so that work could commence on the Project (as that term is defined in the Initiation Agreement) while QIAGEN and BMS [&#8230;***&#8230;] for the [&#8230;***&#8230;] of diagnostic products based on Project [&#8230;***&#8230;] (the &#8220;[&#8230;***&#8230;<font style="text-decoration:underline;">]</font>&#8221;);<font style="margin-left:36pt;"></font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">WHEREAS, the Initiation Agreement allows QIAGEN to engage HTG to perform certain work for which QIAGEN is responsible under the Initiation Agreement in furtherance of the Project, subject to the approval of BMS; </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">WHEREAS, HTG and BMS entered into a Collaboration Agreement having an effective date of May 11, 2016 (the &#8220;<font style="text-decoration:underline;">HTG/BMS Collaboration Agreement</font>&#8221;);</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">WHEREAS, QIAGEN wants to engage HTG to perform certain of the work that is part of the Project and, HTG is willing to perform the work designated to HTG in the Project Plan (as that term is defined in the Initiation Agreement) in the form provided to HTG b